MOMO'S BREAKOUT BOARD

[dirkv]

Back to $1.5 - $2?

Jaguar health (jagx): premarket $1.23 + 32.26%
52w: $0.88 – $11.79

https://www.streetinsider.com/SEC+Filings/Form++SC+13G+++++Jaguar+Health%2C+Inc.++++++++++++++++++++Filed+by%3A+Oasis+Capital%2C+LLC/19448851.html

Dec 22, 2021 1.2800 1.3300 1.1600 1.1800 1.1800 7,525,300
Dec 21, 2021 1.1500 1.8850 1.1400 1.3800 1.3800 88,588,700
Dec 20, 2021 1.1000 1.1700 1.0800 1.1500 1.1500 870,30

December 22, 2021
The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea (CID) in dogs.
• This is the first and only product indicated for treating chemotherapy-induced diarrhea (CID) in dogs to receive any approval from the FDA.
• According to the American Veterinary Medical Association, approximately 1 in 4 dogs will develop a tumor at some stage in their lives, and almost 50% of dogs over age 10 will develop cancer.
• According to the National Cancer Institute, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.
• Canalevia-CA1 will be marketed as a prescription drug product under the company's Jaguar Animal Health tradename. Jaguar will be sharing more details surrounding the commercialization plan for Canalevia-CA1 in early January 2022.
• Crofelemer is an oral plant-based medicine extracted and purified from the red bark sap, also referred to as "dragon's blood," of the medicinal Croton lechleri tree in the Amazon Rainforest.
• Jaguar Health's wholly-owned subsidiary, Napo Pharmaceuticals, has established a sustainable harvesting program for crofelemer.